Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789822 | 1.00 | KDM1A (0.36) | KDM1AHTR6PGRARNOTUM | |
| SCHEMBL23123259 | 0.86 | HTR6 (0.44) | KDM1AHTR6NOTUM | |
| SCHEMBL29789894 | 0.86 | HTR6 (0.44) | KDM1AHTR6NOTUM | |
| SCHEMBL29789734 | 0.81 | KDM1A (0.35) | KDM1A | |
| SCHEMBL23124176 | 0.81 | KDM1A (0.35) | KDM1A | |
| SCHEMBL23123339 | 0.71 | DRD3 (0.42) | KDM1AHTR6 | |
| SCHEMBL29789720 | 0.71 | DRD3 (0.42) | KDM1AHTR6 | |
| SCHEMBL23123704 | 0.69 | AR (0.38) | PGRAR | |
| SCHEMBL23123288 | 0.69 | KDM1A (0.34) | KDM1APGR | |
| SCHEMBL29789801 | 0.69 | AR (0.38) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021055630-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL- BIOTECH INVESTMENTS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | KDM1A 1731/4885HTR6 1493/4885PGR 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.